Effects of recombinant human basic fibroblast growth factor on restenosis after arterial endothelial injury in rats.
OBJECTIVE
To study the preventive effect of recombinant human basic fibroblast growth factor (rh-bFGF) on restenosis after percutaneous transluminal coronary angioplasty (PTCA).


METHODS
Sixty male Wistar rats were randomly divided into sham operation group, intima injured group, and intima injured plus rh-bFGF treated group. Rat carotid arteries were injured using a balloon catheter except sham operation group. The rats of rh-bFGF treated group were injected im rh-bFGF 10 kU . kg-1 . d-1 after intima was injured. Ten rats in each group were killed on d 7 and d 14 after injury, respectively. [3H]Thymidine incorporation assay and pathological examination were carried out to each vessel.


RESULTS
(1) Seven days after injury, the average intimal thickness in sham operation group, intima injured group, and rh-bFGF treated group was (7 +/- 1), (32 +/- 11), and (17 +/- 3) micron; average intimal area was (384 +/- 145), (1530 +/- 817), and (586 +/- 185) micron2; the numbers of smooth muscle cells in neointima per transect were 0 +/- 0, 146 +/- 18, and 105 +/- 26; the ratio of the collagen area to intimal area plus medial area were 0.29 +/- 0.09, 0.7 +/- 0.3, and 0.30 +/- 0.14; [3H]thymidine incorporation were (17 +/- 6), (62 +/- 23), (20 +/- 8) kBq/g tissue, respectively. (2) Fourteen days after injury, the average intimal thickness of sham operation group, intima injured group, and rh-bFGF treated group was (8 +/- 1), (41 +/- 9), and (20 +/- 3) micron; average intimal area was (391 +/- 134), (1761 +/- 337), and (731 +/- 124) micron2; the numbers of smooth muscle cells in neointima per transect were 0 +/- 0, 145 +/- 9, and 102 +/- 6; the ratio of collagen area to intimal area plus medial area were 0.28 +/- 0.14, 0.59 +/- 0.21, and 0.38 +/- 0.03; [3H]thymidine incorporation was (15 +/- 4), (57 +/- 11), and (22 +/- 6) kBq/g tissue, respectively.


CONCLUSIONS
Large dosage of rh-bFGF inhibits neointimal hyperplasia and reduces restenosis after balloon injury.
Chang
L
L
Department of Pharmacology, Lanzhou Medical College, Lanzhou 730000, China.
Zhang
C
C
Wu
Y J
YJ
Zhu
R Z
RZ
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D017536:Carotid Artery, Common / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D023903:Coronary Restenosis / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000473:pathology*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006965:Hyperplasia; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000473:pathology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2